Indivior Pharmaceuticals, Inc. 8-K

What Happened
Indivior Pharmaceuticals, Inc. announced on March 17, 2026 that it issued $500 million principal amount of 0.625% Convertible Senior Notes due 2031 under an indenture with U.S. Bank Trust Company, N.A. The offering included $50 million of notes sold pursuant to the initial purchasers’ full option. Interest accrues at 0.625% per year, payable semi‑annually beginning September 15, 2026, and the notes mature March 15, 2031. Conversions will be settled in cash, stock, or a combination at the company’s election; the initial conversion rate is 24.0033 shares per $1,000 principal (≈ $41.66 per share), about a 35% premium to the March 12, 2026 closing price. Indivior used part of the proceeds to prepay in full and terminate its November 4, 2024 Note Purchase Agreement.

Key Details

• Total issued: $500,000,000 principal amount of 0.625% Convertible Senior Notes due 2031 (includes $50M from option exercise).
• Conversion terms: initial conversion rate 24.0033 shares/$1,000 (initial conversion price ≈ $41.66/share), ~35.0% premium to March 12, 2026 market price.
• Timing/convertibility: interest paid March 15 & Sept 15 (first payment 9/15/2026); conversions generally allowed at holders’ election from Dec 16, 2030 until two scheduled trading days before maturity; earlier conversions only upon specified events.
• Redemption/repurchase: Company may redeem (subject to conditions) beginning March 20, 2029 if stock trades above 130% of the conversion price under specified trading‑day tests; noteholders can require cash repurchase upon certain Fundamental Changes.
• Capital actions: Proceeds were used to prepay all outstanding principal, accrued interest and fees under the company’s Nov. 4, 2024 Note Purchase Agreement, which terminated March 17, 2026.

Why It Matters
This transaction provides Indivior with additional low‑cost, long‑dated financing while eliminating the earlier note purchase facility. The 0.625% coupon is modest, which reduces near‑term interest expense compared with higher‑rate debt, but the securities are convertible and could dilute shareholders if conversions occur. Investors should note the conversion price premium (≈35%) and that conversions are restricted until late 2030 except in defined circumstances; the notes are senior unsecured obligations and are structurally subordinated to liabilities of Indivior’s subsidiaries.